人诱导性多能干细胞向红系分化的研究进展  

Research progress on erythroid differentiation of human induced pluripotent stem cells

作　　者：陈妙纯 吴高椿 刘韬 Chen Miaochun;Wu Gaochun;Liu Tao(Shantou University Medical College,Shantou 515063,China;Department of Tumor Immunotherapy,Shenzhen Luohu People's Hospital,the Third Affiliated Hospital of Shenzhen University,Shenzhen 518001,China)

机构地区：[1]广东汕头大学医学院,汕头515063 [2]深圳市罗湖区人民医院(深圳大学第三附属医院)肿瘤免疫科,518001

出　　处：《中华细胞与干细胞杂志（电子版）》2022年第2期115-120,共6页Chinese Journal of Cell and Stem Cell（Electronic Edition）

基　　金：深圳市科技创新委员会资助基础研究项目(JCYJ20170412155231633)。

摘　　要：红细胞输注对于重症贫血等血液病患者来说是主要的治疗手段,可以降低发病率和死亡率。目前红细胞来源主要依靠无偿献血,但是存在血液资源紧张、血型相容性(ABO和Rh抗原)和感染风险增加等挑战。体外诱导干细胞分化为成熟红细胞有望解决上述难题。人诱导性多能干细胞(iPSCs)具有无限增殖和多向分化能力,在体外经过定向诱导分化可以获得大量的红细胞,满足临床对红细胞的大量需求。本文将对人iPSCs向红系分化的技术发展和临床应用进行综述。Red blood cell transfusion is the main treatment for patients with severe anemia and other hematological diseases,which can reduce morbidity and mortality.At present,the source of red blood cells mainly relies on voluntary blood donation,but there are challenges such as shortage of blood resources,blood group compatibility(ABO and Rh antigens)and increased risk of infection.Differentiation of stem cells into mature erythrocytes in vitro is expected to solve the above problems.Human induced pluripotent stem cells(iPSCs)have unlimited proliferation and multi-directional differentiation ability,and can obtain a large number of erythrocytes after directional induction and differentiation in vitro,meeting the clinical demand for erythrocytes.This article will review the technical development and clinical application of erythroid differentiation of human iPSCs.

关 键 词：红细胞输注 诱导性多能干细胞 红系分化 临床应用 

分 类 号：R32[医药卫生—人体解剖和组织胚胎学]